Teva Sees Innovative Revenue Potential Of $6 Billion to $7 Billion By 2030

By Reuters News

- Teva Pharmaceutical Industries Limited TEVA.TA:

  • TEVA: SEES INNOVATIVE REVENUE POTENTIAL OF $6 BILLION -7 BILLION BY 2030

  • TEVA: FREE CASH FLOW TARGET OF MORE THAN $3.5 BILLION BY 2030

  • TEVA: EXPECTS TOTAL REVENUE OF MID-SINGLE-DIGIT GROWTH FROM 2026 TO 2030

Further company coverage: TEVA.TA

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk